Volume 45 Number 3

The WCET® Journal welcomes contributions in the fields of wound, ostomy and continence care

PDF

中文

You are invited to submit your original research articles, reviews (of research, practice and literature), case studies, clinical trials, commemntaries, updates and letters to the editor to the WCET® Journal. Contributions can relate to the clinical, administrative, research and/or educational roles of the ET Nurse in the fields of wound, ostomy and continence care.

Author guidelines

Submissions

Submissions to the journal are an important way for the WCET® to accomplish its mission of facilitating the ongoing education of ETNs and other clinicians or administrators who may provide direct clinical care or oversee service delivery to the person with a wound, stoma or continence issue.

Submissions to the WCET® Journal should take the form of original research articles, reviews (of research, practice and literature), case studies, clinical trials, commentaries, updates and letters to the editor. They will be accepted from any country but must be written in English. If an article is published in the journal it may be translated into other languages by certified independent translation companies. Please note that the WCET® Journal does not accept responsibility for errors and omissions which may occur when publishing non-English text.

The submitting author must certify that all authors have seen and approved the manuscript content and that the work has not previously been published. Copyright ownership of all articles published in WCET® Journal passes to the World Council of Enterostomal Therapists® (unless prior copyright exists of a small part of an article eg figure or table and permission has been granted for its use).

All work is copy-edited to journal style. The editors reserve the right to modify the style and length of any article so that it conforms to journal format. Major changes to an article will be referred to all authors for approval prior to publication. Major editorial support may be added to the acknowledgements section.

Accepted articles may be co-published in Advances in Skin and Wound Care
https://journals.lww.com/aswcjournal/pages/default.aspx

Manuscript types

The journal publishes articles of interest in the areas of wound, ostomy and continence. Submitted work may take any of the following forms:

Original research
A maximum of 4000 words in the main text plus up to 50 references in a structured form describing the research. The abstract, references, tables and figure legends are excluded from the word count, as are acknowledgements and other end matter. All research should comply with the International Committee of Medical Journal Editors (ICMJE) ‘Protection of Research Participants’ guidelines.

Review
A maximum of 3000 words in the main text plus up to 40 references. A review describes and evaluates the current knowledge of a subject, identifies gaps or inconsistencies and includes critical evaluation with recommendations for future research.

Case study
A maximum of 2000 words. A clinical case study is a combination of a recount (retelling of clinical events as they occurred) and an information report (classification and description of something) and can be presented in different ways to give a cohesive account of clinical events or information.

Clinical trial
A maximum of 4000 words in the main text plus up to 50 references of the trial. The abstract, references, tables and figure legends are excluded from the word count, as are acknowledgements and other end matter.

Commentary
A maximum of 2000 words giving an opinion, interpretation, analysis, or evaluation of an article, guideline or standard.

Update
A maximum of 2000 words giving an insight, analysis, explication, evaluation or reaction about a change in protocols, processes or procedures, including translating research and knowledge into practice.

Letter to the editor
A maximum of 1000 words, plus eight references and normally no more than one table or one figure.

Authorship

All authors must meet all four criteria for authorship based on the ICMJE Recommendations (for the conduct, reporting, editing and publication of scholarly work in medical journals).

  1. Substantial contributions to the conception or design of the work; or the acquisition, analysis or interpretation of data for the work; AND
  2. Drafting the work or revising it critically for important intellectual content; AND
  3. Final approval of the version to be published; AND
  4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

All authors and contributors (ie individuals who contributed to the preparation of the manuscript but who do not meet the ICMJE criteria for authorship, including medical writers/editors) must specify their individual contributions at the end of the text in the acknowledgements section. Individuals who did not contribute to the manuscript development but who deserve to be acknowledged for their contribution to the study (eg study investigators, persons who provided important technical expertise should be mentioned in the acknowledgements section.

Artificial Intelligence

Authors who use AI tools in the writing of a manuscript, production of images or graphical elements of the paper, or in the collection and analysis of data, must be transparent in disclosing in the paper and during the submission process how the AI tool was used and which tool was used. Authors are fully responsible for the content of their manuscript, even those parts produced by an AI tool, and are thus liable for any breach of publication ethics.

Authors must comply with ICMJE sections 3 and 4 of defining the role of authors and contributors in respect of the use of AI.

Permissions

If the author wishes to reproduce copyrighted work, it is the responsibility of the author to obtain written permission from the copyright holder and to upload the original copy of that permission as a cover letter at step 5 of the submission process.

Acknowledgements

Acknowledgements should be as brief as possible. Contributions from anyone who does not meet the criteria for authorship should be listed. For individuals thanked in this section, or acknowledged elsewhere in the text, please provide names (initials and surname) and affiliations. Any editorial assistance should be acknowledged.

Conflict of interest

The conflict of interest section in the manuscript submission process must be answered. It is the responsibility of all authors to disclose any financial and non-financial relationships that could be viewed as presenting a potential or actual conflict of interest. Conflicts of interest must be disclosed within the manuscript before the ethics statement. If this affects the anonymity of authors, it should be disclosed in the title page and not appear in the main document. If there are no conflicts of interest to report, please insert the following statement: “The author(s) declare(s) no conflict of interest.”

Ethics statement

A statement of ethics considerations must be provided after the conflict of interest statement. If this affects the anonymity of authors, it should be included in the title page and not appear in the main document. If an ethics statement is not applicable, this must be stated and justification provided.

Funding

Please include a separate funding section after your acknowledgements which details your sources of funding. Any grant support that requires acknowledgement should be mentioned. The names of funding organisations should be written in full. If this affects the anonymity of authors, it should be disclosed in the title page and not appear in the main document. Where a funding source is declared, the role of the funding source (eg in-study design, data collection, analysis or interpretation of the data) must be described. If the funding source had no such involvement, this must be stated. Where no specific funding was received, please insert the following statement: “The author(s) received no funding for this research/review/study/trial.”

Parts of the manuscript

Title page
The title page must be a Word file and include:

  • An informative title which should not contain abbreviations;
  • A running head (abbreviated title if appropriate);
  • The full names of the authors, including first name, middle name, and last name of each author, with highest academic degree(s) and institutional affiliations;
  • The name and address of the corresponding author, including email address;
  • The total word count.

Main document
As papers are double-blind peer reviewed, the main text file should not include any information that might identify the authors. The main document must be a Word file and should be presented in the following order:

1. Title, structured abstract, key words;

2a. Main text - Original research, Reviews and Clinical trials: Introduction (Background for Clinical trials) Methods, Results, Discussion, Conclusion, Acknowledgements, Conflict of interest, Ethics, Funding;

2b. Main text - Clinical case studies: Introduction, Case presentation, Management and outcomes, Discussion, Conclusion, Acknowledgements, Conflict of interest, Ethics, Funding; (see CARE checklist);

3. Tables (should be a Word file with each table complete with title and footnotes);

4. Figures, including photograhs (must be jpegs);

5. Figure legends;

6. References;

7. Appendices (if relevant).

Figures and tables should also be supplied as separate files.

Abstract and keywords
All manuscript types except letters require abstracts of no more than 250 words. Abstracts for original research, reviews and clinical trials should be structured into four paragraphs: 1) Aims/hypothesis; 2) Methods; 3) Results; 4) Conclusions/interpretation. The abstract should contain data to support the main results of your paper without using unexplained abbreviations. For randomised controlled trials (RCTs), abstracts should include the checklist items set out in the CONSORT guidelines. If data have been deposited in a public repository, authors should include the dataset name and repository name and number at the end of the abstract.

Up to five key words should be provided in alphabetical order at the end of the abstract.

Abbreviations
Please use abbreviations only when necessary and define them in a separate list, in alphabetical order, given after the keywords. Abbreviations should not normally appear in the title or abstract.

Introduction
The Introduction should contain a clear statement of the aim and novelty of the paper. It should not include results nor conclusions.

Methods
Enough information should be given to allow a knowledgeable reader to understand what was done, and how, and to assess the relevance of the study and the reliability and validity of the findings. The methods must be detailed enough that others with access to the data would be able to reproduce the results.

Clinical trials mentioned in the text
The ICMJE recommends that where clinical trials are mentioned, for example in secondary analyses or meta-analyses, the trial registration number should be included at the first mention of the trial in the manuscript.

Description of patients/participants
Detailed descriptions should be provided of the individuals’ clinical or study participant’s characteristics upon which individuals were classified.

Informed consent and ethics committee approval
Human investigations

A paper describing experimental work in humans must also include in the methods section: (1) a statement that indicates that informed consent has been obtained from patients where appropriate; (2) a statement that the responsible ethics committee (institutional review board) has given approval, and/or indicate that the reported investigations have been carried out in accordance with the principles of the Declaration of Helsinki as revised in 2008. Do not use participant names, initials nor hospital numbers, especially in illustrative material.

Animal investigations

Manuscripts reporting data obtained from research using animals must include a statement of assurance that all animals received humane care. Study protocols must comply with the institution’s guidelines. Further guidance on animal research ethics is available here.

Statistical analyses
Describe statistical methods in sufficient detail to enable a knowledgeable reader with access to the original data to verify the reported results. Where possible, quantify findings and present them with appropriate indicators of measurement error or uncertainty. See ICMJE paragraph on statistics.

Results
The results should be stated concisely without discussion and should not normally contain any references. The same data should not be presented in figures and tables. Do not repeat all the data that are set out in the tables or figures in the text; emphasise or summarise only important observations.

Discussion
The discussion should deal with the interpretation of the results and not recapitulate them. It could include: a statement of principal findings; the strengths and weaknesses of the study; the strengths and weaknesses in relation to other studies, discussing important differences in results; the meaning of the study; possible explanations and implications for clinicians and policymakers; unanswered questions; and future research.

Conclusion
If appropriate, a conclusion may be included which may suggest some further research, give a concluding statement and/or pose a further question.

Referencing guidelines

The referencing must be Vancouver style, the main feature of which is the use of superscript numbers at the point of reference so as not to interfere with the flow of words. Each number corresponds to a single reference provided in the reference list at the end. Once assigned a number, a reference retains that number throughout the text, even if cited more than once. Following are some examples of reference formats using the Vancouver style:

Articles in journals

  • Standard journal article: list all authors if less than four, if four or more list first three followed by et al:
    Whitby DJ, Ferguson MW. Immunohistochemical localisation of growth factors in fetal wound healing. Dev Biol 1991;147:207–15.
    Jeffrey JJ, Ehlich LS, Roswit WT et al. Serotonin: an inducer of collagenase in myometrial smooth muscle cells. J Cell Physiol 1991;146:399–406.
  • Organisation as author:​​​​​​
    ​The Royal Marsden Hospital Bone-Marrow Transplantation Team. Failure of syngenic bone-marrow graft without preconditioning in post-hepatitis marrow plasma. Lancet 1977;2:742–44.
  • No author given:
    Coffee drinking and cancer of the pancreas (Editorial). BMJ 1981;283:628.
  • Volume with supplement:
    Magni F, Rossoni G, Berti F. BN-62021 protects guinea-pig from heart anaphylaxis. Pharmacol Res Commun 1988;20(Suppl 5):75–78.
  • Issue with supplement:
    Gardos G, Cole JO, Haskell D et al. The natural history of tardive dyskinesia. J Clin Psychopharmacol 1988;4(4 Suppl):31S–37S.

Books and other monographs

  • Personal author(s):
    Majno GA. The healing hand: man and wound in the ancient world. Cambridge: Harvard University Press; 1975.
  • Chapters in a book:
    Philips C, Wenstrup RJ. Biosynthetic and genetic disorders of collagen. In: Cohen IK, Diegelmann RF, Lindblad WJ, editors. Wound healing: biochemical and clinical aspects. Philadelphia: Saunders; 1992. p. 152–71.
  • Conference proceedings:
    Harley NH. Comparing radon daughter dosimetric and risk models. In: Gammage RB, Kaye SV, editors. Indoor air and human health. Proceedings of the Seventh Life Sciences Symposium; 1984 Oct 19–31; Knoxville (TN). 

Tables and figures

Tables should be submitted as Word files and clearly typed, showing columns and lines. Number tables consecutively using Arabic numerals in the order of their first citation in the text and supply a brief title for each. Place explanatory matter in footnotes, not in the heading. Explain in footnotes all non-standard abbreviations used in each table.

Figures must be submitted as separate high-resolution jpegs, at least 300 KB in size and no larger than 2MB. They must be clearly numbered and identified when files are uploaded. Patients or other individual subjects should not be identifiable from photos unless they have given written permission for their identity to be disclosed; this must be supplied.

Submission of manuscripts

Submissions will only be accepted via the WCET® Journal ScholarOne website. To submit manuscripts, go to https://mc04.manuscriptcentral.com/wcet and log into your Author Centre. ‘Submit an Article’ links can be found at wcetn.org, journals.cambridgemedia.com.au/wcetcn, journals.cambridgemedia.com.au/wcetes, journals.cambridgemedia.com.au/wcetfr and journals.cambridgemedia.com.au/wcetpt

The title page, main document, tables and figures are to be uploaded separately. The main document must not contain names of authors – these should only appear in the title page. The main document may include the tables and figures to show their preferred positions. However, tables and figures can sometimes become corrupted when embedded in Word files which is why they must also be uploaded separately.

To create an account when using the system for the first time, click on ‘Create an Account’ in the login screen. Please enter as much information as possible when creating an account.

Once in the system, the steps to submit an article are:

• Step 1 – Manuscript type, title and abstract;

• Step 2 – Upload files;

• Step 3 – Add key words – at least two are required, up to five allowed;

• Step 4 – Add co-author and edit your details (if necessary);

• Step 5 – Add manuscript information and questions on funding, ethics, conflict of interest and copyright;

• Step 6 – Review and submit.

Submitted manuscripts are acknowledged by a system-generated email.

The ScholarOne website has comprehensive guidelines and online tutorials to assist in using the system. Click on ‘Help’ in the top right hand corner and choose ‘Author’ as your role to access author guides.

Peer review process

The acceptance criteria for all papers are the quality and originality of the manuscript and its significance to the journal readership. All manuscripts are double-blind peer reviewed. Papers will only be sent to review if the editor determines that the paper meets the appropriate quality and relevance requirements. The editor’s decision is final.

If the manuscript does not conform to the submission guidelines, the author will be asked to amend prior to peer review. The peer review process is managed online in the ScholarOne system. Decisions are communicated by system-generated emails to the corresponding author.

Resubmission of revised manuscripts

If you are asked to revise your manuscript, you will be expected to respond in detail to each point raised by reviewers and/or editors in ‘View and Respond to Decision Letter’ Step 1 of the resubmission process. If points made by reviewers are not addressed, the manuscript will be returned or rejected.

At step 3, remove files that have been revised and upload the revised files. Use a different colour font to indicate all changes (including deletions) and new material in your paper, ensuring that such changes will be clear if referees print your manuscript in black and white (do not use the ‘track changes’ mode of Word). A clean copy (without coloured font and deletions) of the revised main document must also be uploaded.


期待您的投稿!共同推动伤口、造口与失禁护理的发展

PDF

欢迎向《WCET® Journal》投稿,内容形式包括:原创研究文章、综述(研究综述、临床实践综述、文献综述)、病例报告、临床试验、评论文章、护理动态以及致编辑信等。来稿主题可围绕伤口、造口与失禁护理领域中,造口治疗护士在临床护理、管理实践、科研探索或教育培训等方面的角色与经验展开。

作者指南

投稿须知

向本期刊投稿是WCET®践行其使命的重要方式之一,旨在持续促进造口治疗护士及其他临床医师或管理人员的专业教育与发展,无论他们是直接为伤口、造口或失禁患者提供临床护理,还是负责相关服务的组织与管理。

《WCET® Journal》接受以下类型的稿件:原创研究文章、综述(涵盖研究、实践及文献)、病例研究、临床试验、评论文章、最新动态与致编辑信等。我们欢迎来自世界各地的来稿,但所有稿件必须以英语撰写。如稿件被本刊录用,可由经认证的第三方专业翻译公司翻译为其他语言版本。请注意,《WCET® Journal》不对非英文稿件在翻译或出版过程中可能出现的任何错误或遗漏承担责任。

供稿作者必须证明所有合著者均已审阅并批准稿件内容,且稿件未曾在其他出版物中发表。所有在WCET®期刊上发表的文章的版权归世界造口治疗师委员会®所有(若文章中包含已有版权的图表或内容,须获得相应授权方可使用)。

所有稿件均将根据期刊的格式要求进行文字编辑。编辑部保留对文章体例和篇幅进行必要修改的权利,以确保其符合期刊规范。若对稿件内容进行重大修改,编辑部将在发表前征得全体作者的同意。若稿件在编辑过程中获得了较多编辑协助或专业支持,相关信息可在“致谢”部分注明。

部分被接收的优秀稿件可能会同步发表于国际权威期刊《Advances in Skin and Wound Care》:https://journals.lww.com/aswcjournal/pages/default.aspx

稿件类型

本刊主要刊登与伤口、造口及失禁护理相关的文章。投稿内容可包括以下类型:

原创研究

正文部分不超过4000字,参考文献不超过50条。文章应以结构化形式描述研究内容。摘要、参考文献、表格、图例说明、致谢及其他附录部分不计入字数限制。所有研究类稿件均应遵循《国际医学期刊编辑委员会(ICMJE)》的〈研究参与者保护指南〉。

综述

正文部分不超过3000字,参考文献不超过40条。综述类文章应总结并评估某一主题的现有知识,指出其中的不足或不一致之处,并进行批判性分析,同时提出未来研究的方向或建议。

病例研究

正文部分不超过2000字。临床病例研究应结合病例叙述(按事件发生顺序重述临床经过)与信息报告(对某一现象的分类与描述),可采用不同方式呈现,以提供连贯完整的临床事件或信息记录。

临床试验

正文部分不超过4000字,参考文献不超过50条。摘要、参考文献、表格、图例说明、致谢及其他附录部分不计入字数限制。

评论

正文部分不超过2000字,用于对某篇文章、指南或标准进行评论、解读、分析或评估。

更新

正文部分不超过2000字。此类文章应对临床方案、流程或操作规程的变更进行分析、解读、评估或回应,也可包括将最新研究成果或知识转化为实践的相关内容。

致编辑信

正文部分不超过1000字,可引用的参考文献不超过8条,通常不应包含超过1张表格或一张图表。

作者署名资格

所有作者必须符合ICMJE关于医学期刊学术工作撰写、编辑与发表的推荐标准中所列的四项作者资格标准。

1. 在研究构思或设计,或数据采集、分析或解读方面作出实质性贡献;且

2. 负责撰写论文初稿,或对其重要学术内容进行关键性修改;且

3. 对拟发表的最终版本进行审阅并批准;且

4. 同意对研究的所有方面承担责任,确保有关研究准确性或完整性的问题得到适当调查与解决。

所有作者和贡献者(即参与稿件准备但不完全符合ICMJE作者资格标准的人员,包括医学写作者或编辑)均须在正文末尾的致谢部分中明确说明其个人贡献。此外,未直接参与稿件撰写但在研究中作出重要贡献的人员(例如研究调查者、提供关键技术支持的人员),也应在致谢部分中予以说明。

人工智能(AI)

作者在使用AI工具撰写稿件、生成图片或图形元素,或在数据收集与分析过程中使用AI时,必须在论文中以及投稿流程中明确说明所使用的AI工具及其用途。作者对其稿件的全部内容承担全部责任,包括由AI工具生成的部分。因此,作者应对任何违反出版伦理的行为承担相应责任。

作者在使用AI工具时,必须遵守ICMJE第3和第4部分关于作者和贡献者角色定义中有关AI使用的规定。

版权许可

若作者希望在稿件中引用或转载受版权保护的内容,作者有责任向版权持有人获取书面许可,并在投稿流程的第5步上传该许可文件的原件作为附函。

致谢

致谢部分应尽量简明扼要。凡未满足作者署名条件但对研究或稿件有贡献的人员,均应在此部分列出。对于在文中致谢的个人,请注明其姓名(首字母与姓氏)及所属机构。如稿件在撰写或编辑过程中获得的协助,也应在此部分予以说明。

利益冲突声明

在稿件提交过程中,必须填写利益冲突声明。所有作者有责任披露任何可能被视为潜在或实际利益冲突的财务和非财务关系。利益冲突声明应在稿件中置于伦理声明之前。若披露该信息可能影响作者的匿名性,应将其放在标题页,而不出现在正文中。若作者不存在任何需披露的利益冲突,请在稿件中注明以下声明:“作者声明不存在利益冲突。”(英文原文:The author(s) declare(s) no conflict of interest.)

伦理声明

在利益冲突声明之后,作者必须提供伦理相关声明。若披露该信息可能影响作者的匿名性,应将其放在标题页,而不出现在正文中。若研究不适用伦理声明,亦须在稿件中明确说明并提供合理说明理由。

资助信息

请在致谢部分之后单独提供资助信息,详细说明本研究的资金来源。任何需要致谢的资助项目或基金支持均应在此部分中明确说明,资助机构的名称须完整写出。若披露资助信息可能影响作者匿名性,应将其放置于标题页,而不出现在正文中。若声明了资助来源,则须说明资助方在研究中的角色(例如:是否参与研究设计、数据收集、数据分析或数据解读等)。若资助方未参与研究的任何环节,亦须在稿件中加以说明。如研究未获得任何专项基金资助,请使用以下声明:“作者声明,本研究/综述/课题/试验未获得任何资助。”(英文原文:The author(s) received no funding for this research/review/study/trial.)

稿件组成部分

标题页

标题页须为Word文件,并应包含以下内容:

• 标题应准确反映研究内容,且不得使用缩写词;

• 短标题(如适用,可采用简略形式);

• 所有作者的完整姓名,包括每位作者的名字、中间名和姓氏,并标注最高学历及所属机构;

• 通讯作者姓名及详细联系方式(含电子邮箱);

• 稿件总字数。

主文稿

由于本刊实行双盲同行评审制度,主文稿文件中不得出现任何可识别作者身份的信息。主文稿须为Word文件,并按以下顺序编排:

1. 标题、结构化摘要、关键词;

2a. 主体部分(适用于原始研究、综述和临床试验类稿件):引言(临床试验背景)、方法、结果、讨论、结论、致谢、利益冲突、伦理声明、资助信息;

2b. 主体部分(适用于临床病例研究类稿件):引言、病例介绍、管理与结局、讨论、结论、致谢、利益冲突、伦理声明、资助信息(见CARE清单);

3. 表格(Word文件,需包含完整标题和脚注);

4. 图片(包括照片,格式须为JPEG);

5. 图例说明;

6. 参考文献;

7. 附录(如适用)。

此外,所有图表均须另行作为独立文件提交。

摘要和关键词

除致编辑信外,所有类型的稿件均须附不超过250字的摘要。原创研究、综述及临床试验的摘要应采用结构化格式,分为四个部分:1)目的/假设;2)方法;3)结果;4)结论/解读。摘要应包含足以支撑主要结果的数据,且不得使用未定义或无法解释的缩略词。对于随机对照试验(RCT),摘要应符合CONSORT指南的要求,包含相关核对清单中的项目。如果研究数据已存入公共存储库,作者须在摘要末尾注明数据集名称、数据库名称及编号。

在摘要末尾应按字母顺序列出不超过五个关键词。

缩略词

仅在确有必要时方可使用缩略词。所有缩略词须在稿件中单独列出清单,按字母顺序排列,置于关键词之后。通常情况下,缩略词不应出现在标题或摘要中。

引言

引言应包含对本文研究目的和创新性的明确陈述。不得在引言部分包含结果或结论。

方法

应提供足够的信息,使具有相关知识的读者能够理解研究的实施过程和方法,并能够评估研究的相关性、结果的可靠性和有效性。方法部分必须详细到使其他研究者在获得相同数据的情况下能够重复研究结果。

文中提及的临床试验

ICMJE建议:凡在文中提及临床试验(如二次分析或荟萃分析)时,应在稿件中首次提及该试验时标明其试验注册号。

患者/参与者描述

应提供研究对象或受试者的详细特征描述,并说明用于研究分组或分类的依据。

知情同意和伦理委员会批准

人体研究

凡涉及人体实验研究的论文,必须在方法部分中包含以下说明:(1)明确声明已在适当情况下获得受试者的知情同意;(2)声明研究已获得伦理委员会(机构审查委员会,IRB)批准,并/或说明该研究符合经2008年修订的《赫尔辛基宣言》所确立的原则。在论文中,尤其是插图或影像资料中,不得使用参与者姓名、姓名首字母或医院编号等可识别个人身份的信息。

动物研究

凡报告动物实验数据的稿件,必须在文中明确声明,所有实验动物均得到了人道照护。研究方案须符合所在机构的相关指南或规定。有关动物实验伦理的进一步指导,请参阅相关伦理规范

统计分析

应对统计方法进行充分详细的描述,使具备相关知识的读者在获得原始数据的情况下能够验证所报告的结果。在可能的情况下,应对研究结果进行定量描述,并使用适当的误差或不确定性指标进行说明。有关统计学报告的更多指导,请参阅ICMJE统计学章节。

结果

结果部分应简明扼要地陈述研究发现,不应包含讨论,且通常不应包含参考文献。相同的数据不应同时在图表和表格中呈现。不要在正文中重复表格或图片中的所有数据,应仅强调或总结关键观察结果。

讨论

讨论部分应侧重于对结果的解读,而非对结果的重复描述。内容可包括:主要研究发现的总结;本研究的优势与局限性;与其他研究比较时的优势与不足,并讨论结果的显著差异;研究的意义;对临床医生和政策制定者的可能解释与启示;尚未解决的问题;未来的研究方向。

结论

如适用,可包含结论部分提出进一步研究的建议,总结主要观点,或提出值得探讨的新问题。

参考文献格式指南

本刊要求参考文献采用Vancouver引用格式。该格式的主要特点是在正文引用处使用上标数字,以避免影响正文阅读流畅性。每个数字对应于文末参考文献表中的一个文献。文献编号一经分配,在全文中保持不变,即使被多次引用,也使用相同编号。以下为Vancouver格式引用示例:

期刊文章

• 标准期刊论文:如果作者少于4名,应全部列出;如果作者为4名或以上,则列出前三名作者,后接et al:
Whitby DJ, Ferguson MW. Immunohistochemical localisation of growth factors in fetal wound healing. Dev Biol 1991;147:207–15.
Jeffrey JJ, Ehlich LS, Roswit WT et al. Serotonin: an inducer of collagenase in myometrial smooth muscle cells. J Cell Physiol 1991;146:399–406.

• 机构为作者:
The Royal Marsden Hospital Bone-Marrow Transplantation Team. Failure of syngenic bone-marrow graft without preconditioning in post-hepatitis marrow plasma. Lancet 1977;2:742–44.

• 无作者署名:
Coffee drinking and cancer of the pancreas (Editorial). BMJ 1981;283:628.

• 含増刊的卷号:
Magni F, Rossoni G, Berti F. BN-62021 protects guinea-pig from heart anaphylaxis. Pharmacol Res Commun 1988;20(Suppl 5):75–78.

• 含増刊的期号:
Gardos G, Cole JO, Haskell D et al. The natural history of tardive dyskinesia. J Clin Psychopharmacol 1988;4(4 Suppl):31S–37S.

图书和其他专著

• 单一作者书籍:
Majno GA. The healing hand: man and wound in the ancient world. Cambridge: Harvard University Press; 1975.

• 书籍章节:
Philips C, Wenstrup RJ. Biosynthetic and genetic disorders of collagen. In: Cohen IK, Diegelmann RF, Lindblad WJ, editors. Wound healing: biochemical and clinical aspects. Philadelphia: Saunders; 1992. p. 152–71.

• 会议论文集:
Harley NH. Comparing radon daughter dosimetric and risk models. In: Gammage RB, Kaye SV, editors. Indoor air and human health. Proceedings of the Seventh Life Sciences Symposium; 1984 Oct 19–31; Knoxville (TN).†

表格和图片

表格应以Word文件形式提交,格式清晰,包含明确的列线与行线。所有表格应按其在正文中首次出现的顺序以阿拉伯数字连续编号,并为每个表格提供简明的标题。说明性文字应放在表格脚注中,而非标题中。所有非常规缩略词均应在脚注中加以解释。

图片作为单独文件提交,格式为高分辨率JPEG,文件大小应至少为300 KB,且不超过2 MB。上传文件时,图片必须清楚编号并标注。若照片中可识别患者或受试者身份,必须事先获得书面同意,授权其身份在出版物中披露,并随稿件一并提交该许可。

稿件提交

所有稿件须通过《WCET® Journal》的ScholarOne网站提交。请访问以下网址登录“Author Centre”(作者中心):https://mc04.manuscriptcentral.com/wcet。在以下网站也可找到“Submit an Article”(提交文章)链接:wcetn.orgjournals.cambridgemedia.com.au/wcetcnjournals.cambridgemedia.com.au/wcetesjournals.cambridgemedia.com.au/wcetfrjournals.cambridgemedia.com.au/wcetpt

标题页、主文稿、表格和图片必须分别上传。主文稿中不得出现作者姓名,作者信息仅限出现在标题页。正文文件中可以包含表格和图片,以显示作者期望的排版位置。然而,由于Word文件中嵌入的表格和图片有时会损坏,因此表格和图片必须另行单独上传。

首次使用系统时,请在登录界面点击“Create an Account”(创建账户),并尽可能完整地填写个人信息。

进入系统后,投稿流程包括以下六个步骤:

• 第1步-选择稿件类型,填写标题与摘要;

• 第2步-上传文件;

• 第3步-添加关键词(至少2个,最多允许5个);

• 第4步-添加合著者信息,并在需要时修改作者详情;

• 第5步-填写稿件信息及有关资助、伦理、利益冲突和版权的问题;

• 第6步-审核并提交。

已提交的稿件将通过系统自动生成的电子邮件进行确认。

ScholarOne网站提供完整的用户指南与在线教程。点击页面右上角的“Help”(帮助),并选择角色“Author”(作者),即可查阅作者使用手册。

同行评审流程

所有稿件的录用标准包括:研究质量、原创性以及其对期刊读者群的学术价值与相关性。本刊实行双盲同行评审制度。仅当编辑认为稿件符合相应的质量与相关性标准时,方会送交评审。编辑的决定为最终决定。

若稿件未符合投稿指南的要求,作者将在进入评审前被要求进行修改并重新提交。整个同行评审流程通过ScholarOne在线系统进行管理。评审结果及相关决定将通过系统自动生成的电子邮件发送至通讯作者。

修订稿提交

若作者被要求修改稿件,需在重新提交时逐条回复审稿人和/或编辑的意见。此步骤可在重新提交流程的Step 1(View and Respond to Decision Letter)中完成。若作者未对审稿意见作出充分回应,稿件可能被退回或拒稿。

在第3步中,请删除旧版本文件,并上传修订后的新文件。修订稿中所有修改(包括删除和新増内容)须使用不同颜色字体标示,以确保即使审稿人打印为黒白稿件,也能清晰辨识修改部分(请勿使用Word的“修订模式”)。另需上传一份无标记版本,即不含彩色字体和删除痕迹的修订后主文稿。